Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B

Neth J Med. 2008 Nov;66(10):433-7.

Abstract

A 36-year-old male with acute myeloid leukaemia was treated with liposomal amphotericin B for a breakthrough fungal infection with Absidia corymbifera during voriconazole and caspofungin therapy for invasive pulmonary aspergillosis. Four episodes of hyperkalaemia developed with a highly probable relation to infusion of liposomal amphotericin B, of which the last episode was characterised by severe, refractory hyperkalaemia and fatal cardiac arrest. The available literature on severe hyperkalaemia and cardiac arrest during administration of both conventional and liposomal amphotericin B is reviewed here and revealed only four similar cases. The most likely mechanism of toxicity is the release of potassium from a variety of mammal cells including erythrocytes and endothelial cells. Whether prevention of toxicity can be established by decreasing the infusion rate is unclear but conceivable.

Publication types

  • Case Reports

MeSH terms

  • Absidia / isolation & purification
  • Adult
  • Amphotericin B / adverse effects*
  • Amphotericin B / therapeutic use
  • Antifungal Agents / adverse effects*
  • Antifungal Agents / therapeutic use
  • Fatal Outcome
  • Heart Arrest / chemically induced*
  • Humans
  • Hyperkalemia / chemically induced*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / microbiology
  • Male
  • Mucormycosis / drug therapy

Substances

  • Antifungal Agents
  • Amphotericin B